Cargando…
BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients
Androgen receptor (AR) mutations arise in patients developing resistance to hormone deprivation therapies. Here we describe BAY 1024767, a thiohydantoin derivative with strong antagonistic activity against nine AR variants with mutations located in the AR ligand-binding domain (LBD), and against wil...
Autores principales: | Sugawara, Tatsuo, Lejeune, Pascale, Köhr, Silke, Neuhaus, Roland, Faus, Hortensia, Gelato, Kathy A., Busemann, Matthias, Cleve, Arwed, Lücking, Ulrich, von Nussbaum, Franz, Brands, Michael, Mumberg, Dominik, Jung, Klaus, Stephan, Carsten, Haendler, Bernard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868737/ https://www.ncbi.nlm.nih.gov/pubmed/26760770 http://dx.doi.org/10.18632/oncotarget.6864 |
Ejemplares similares
-
Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876
por: Siebeneicher, Holger, et al.
Publicado: (2016) -
Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
por: Sugawara, Tatsuo, et al.
Publicado: (2019) -
Comparative Proteomic and Transcriptomic Analysis of the Impact of Androgen Stimulation and Darolutamide Inhibition
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2022) -
Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents
por: Klingbeil, Olaf, et al.
Publicado: (2016) -
Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies
por: Möller, Carsten, et al.
Publicado: (2018)